Literature DB >> 19336019

Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies.

Elizabeth M Dugan1, Adam M Huber, Frederick W Miller, Lisa G Rider.   

Abstract

Adult and juvenile dermatomyositis, polymyositis and myositis overlapping with another connective tissue disease are rare systemic autoimmune diseases with a primary feature of weakness and muscle inflammation. Cutaneous findings specific to the underlying condition are present in many patients with these disorders. Some lesions are highly characteristic of the idiopathic inflammatory myopathies (IIM), especially in dermatomyositis. Some cutaneous findings are common but not specific to the IIM and others are less frequently observed in patients with these illnesses. Many of these manifestations also have different grades of disease activity or damage. This photoessay reviews the classification and assessment of the cutaneous manifestations of the IIM and presents example photographs of many of the lesions of adult and juvenile IIM accumulated from the clinical experience of international experts in these conditions. The purpose of this work is to facilitate better recognition of the diverse cutaneous manifestations associated with these inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336019

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  10 in total

1.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

2.  Quality of life in dermatomyositis.

Authors:  Renato Goreshi; Monika Chock; Kristen Foering; Rui Feng; Joyce Okawa; Matt Rose; David Fiorentino; Victoria Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-01       Impact factor: 11.527

3.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

Review 4.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

Review 5.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

6.  Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study.

Authors:  N Martin; P Krol; S Smith; L Beard; C A Pilkington; J Davidson; L R Wedderburn
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-11       Impact factor: 4.794

7.  Biologic predictors of clinical improvement in rituximab-treated refractory myositis.

Authors:  Ann M Reed; Cynthia S Crowson; Molly Hein; Consuelo Lopez de Padilla; Jeannette M Olazagasti; Rohit Aggarwal; Dana P Ascherman; Marc C Levesque; Chester V Oddis
Journal:  BMC Musculoskelet Disord       Date:  2015-09-17       Impact factor: 2.362

8.  Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures.

Authors:  Jeannette M Olazagasti; Molly Hein; Cynthia S Crowson; Consuelo Lopez de Padilla; Erik Peterson; Emily C Baechler; Ann M Reed
Journal:  J Inflamm (Lond)       Date:  2015-04-09       Impact factor: 4.981

9.  The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Mona Shah; Gulnara Mamyrova; Adam M Huber; Madeline Murguia Rice; Ira N Targoff; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2013-07       Impact factor: 1.817

Review 10.  The Vasculopathy of Juvenile Dermatomyositis.

Authors:  Charalampia Papadopoulou; Liza J McCann
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.